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Previous studies have demonstrated that mouse hepatitis virus (MHV) hepatotropism is determined largely
by postentry events rather than by availability of the viral receptor. In addition, mutation of MHV nonstruc-
tural protein 2 (ns2) abrogates the ability of the virus to replicate in the liver and induce hepatitis but does not
affect replication in the central nervous system (CNS). Here we show that replication of ns2 mutant viruses is
attenuated in bone marrow-derived macrophages (BMM) generated from wild-type (wt) mice but not in L2
fibroblasts, primary astrocytes, or BMM generated from type I interferon receptor-deficient (IFNAR/) mice.
In addition, ns2 mutants are more sensitive than wt virus to pretreatment of BMM, but not L2 fibroblasts or
primary astrocytes, with alpha/beta interferon (IFN-/). The ns2 mutants induced similar levels of IFN-/
in wt and IFNAR/ BMM, indicating that ns2 expression has no effect on the induction of IFN but rather that
it antagonizes a later step in IFN signaling. Consistent with these in vitro data, the virulence of ns2 mutants
increased to near that of wt virus after depletion of macrophages in vivo. These data imply that the ability of
MHV to replicate in macrophages is a prerequisite for replication in the liver and induction of hepatitis but
not for replication or disease in the CNS, underscoring the importance of IFN signaling in macrophages in vivo
for protection of the host from hepatitis. Our results further support the notion that viral tissue tropism is
determined in part by postentry events, including the early type I interferon response.
Coronaviruses are positive-strand RNA viruses that induce a
wide variety of diseases in both humans and animals. Five to 30
percent of common colds are caused by human coronaviruses
(HCoVs) (44). The emergence of severe acute respiratory syn-
drome coronavirus (SARS-CoV) in 2003 resulted in over 8,000
documented cases of SARS before the outbreak was extin-
guished, with a mortality rate of 9.6%, highlighting the impor-
tance of understanding coronavirus-associated diseases. Mouse
hepatitis virus (MHV), a murine coronavirus, infects several or-
gan systems in laboratory mice, thereby providing models for
virus-induced acute encephalitis, hepatitis, and pneumonitis in a
natural host, as well as for chronic demyelinating diseases such as
multiple sclerosis (8, 44). The MHV model has been used exten-
sively for investigating coronavirus-host interactions, including
elucidating the determinants of tissue tropism and virulence. In-
fections with a collection of recombinant viral strains and mutants
that display different tropisms and virulence levels have demon-
strated that the organ tropism and virulence of MHV depend
on a combination of viral genes and host response factors (21,
23–26).
Comparison of the pathogenesis of wild-type (wt) MHV
strains with different abilities to replicate in the liver and in-
duce hepatitis, namely, the hepatotropic MHV A59 and non-
hepatotropic JHM.SD strains, with recombinant A59/JHM
chimeric viruses demonstrated, perhaps surprisingly, that the
ability to infect the liver did not map to the spike gene, which
encodes the protein responsible for receptor interaction and
viral entry, but rather to background genes, implying that
MHV tropism is due at least in part to postentry mechanisms
(23). One early and effective host defense mechanism against
viral invasion is the type I interferon (IFN; primarily IFN-/)
response. There are published data indicating that basal ex-
pression levels of interferon-stimulated genes (ISGs) vary
among different cell types and organs and can play an impor-
tant role in determining susceptibility to initial viral infection,
thus affecting organ tropism (14, 48). Indeed, the importance
of the type I IFN response for restriction of MHV infection is
implied by the observation that mice deficient in type I IFN
signaling (IFNAR/ mice) exhibit increased viral replication
and spread within and outside the central nervous system
(CNS), loss of organ tropism barriers, and rapid death when
infected with neurovirulent strains of MHV (31).
Despite the important role of type I IFN signaling in protection
from MHV in vivo, most strains of MHV are relatively insensitive
to IFN-/ treatment of cell lines in vitro (30, 32, 43, 47). In
addition, we have observed that IFN-treated neurons are unable
to restrict the replication of MHV (unpublished data). However,
other primary cell types, such as bone marrow-derived macro-
phages (BMM) and microglia, respond to IFN treatment by re-
stricting MHV replication (30; unpublished data). These obser-
vations suggest that MHV has evolved mechanisms to antagonize
the IFN response in a cell-type-specific fashion, which may influ-
ence pathogenesis in vivo.
We have previously shown that the accessory protein non-
structural protein 2 (ns2) expressed by the dual-tropic (hepa-
totropic and neurotropic) MHV A59 strain is a liver-specific
virulence factor that is necessary for the induction of hepatitis
but dispensable for pathogenesis in the CNS (33). The se-
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quence of ns2 places it in the eukaryotic-viral LigT-like family
of 2H-phosphoesterases, proteins involved in splicing during
tRNA processing. As such, ns2 contains two conserved His-X-
Thr/Ser motifs in which the His residues are predicted to be
catalytic; homologous proteins are encoded by other group IIa
coronaviruses as well as by toroviruses and human rotavirus
(20, 39). Such proteins are predicted to have cyclic nucleotide
phosphodiesterase (CPD) and/or RNA ligase activity and thus
could possibly process or modify host or viral RNAs. In sup-
port of this proposed mechanism, mutation of either of the two
predicted catalytic His residues (H46A or H126R mutation)
attenuates A59 replication in the liver and reduces hepatitis to
a minimal level, while substitutions of other amino acids near
the catalytic His residues have no detectable effect on patho-
genesis (33), implicating the activity of CPD in pathogenesis.
However, no enzymatic activity has been demonstrated for ns2.
We show here that MHV ns2 H46A and H126R mutants have
increased sensitivity to type I IFN signaling in BMM but not in
other cell types, implying that ns2 confers a cell-type-specific
ability to antagonize the type I IFN antiviral response in mac-
rophages. We conclude that IFN signaling in macrophages
blocks viral infection of the liver but not of the brain and infer
that the ability of a virus to overcome type I IFN signaling in
macrophages is a prerequisite for invasion of the liver paren-
chyma and subsequent induction of hepatitis.
MATERIALS AND METHODS
Cell lines, plasmids, viruses, and mice. Murine L2 fibroblast cells were main-
tained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), HEPES (10 mM), and 1% penicillin-streptomycin.
Plaque assays were performed on L2 cells as described previously (13). Recom-
binant coronaviruses inf-MHV-A59 (referred to as wt A59 or A59 in this report),
inf-ns2-H126R, and inf-ns2-H46A (referred to as ns2-H126R and ns2-H46A,
respectively, in this report) have been described previously (33). MHV Wb1
(referred to as JHM.WUns2 in this report) and MHV Wb3 (referred to as
JHM.WU in this report) have been described previously (36). Wb1 and Wb3
were both plaque purified from a tissue culture-passaged JHM stock; they are
thus closely related but not isogenic. Both sets of viruses were provided by Stuart
Siddell (University of Bristol, Bristol, United Kingdom). C57BL/6 (B6) mice
were purchased from the National Cancer Institute (Frederick, MD). IFNAR/
mice (B6 background) were obtained from Michael Diamond (Washington Uni-
versity, St. Louis, MO) and were bred in our animal facility as described previ-
ously (32).
Infection of mice. Four- to 5-week-old B6 mice were anesthetized with isoflu-
rane (IsoFlo; Abbott Laboratories) and inoculated intracerebrally (i.c.) in the
left cerebral hemisphere with 10 PFU of JHM.WU or JHM.WU-ns2 in 20 l of
phosphate-buffered saline (PBS) containing 0.75% bovine serum albumin (BSA)
or intrahepatically (i.h.) with 500 PFU of A59 or ns2-H126R in 50 l of PBS
containing 0.75% BSA. At day 5 postinfection, the animals were sacrificed.
Organs were harvested, and viral titers were determined by plaque assay on L2
cells (12, 33). Alternatively, organs were used for immunohistochemistry as
described below. All experimental procedures were approved by the Univer-
sity of Pennsylvania IACUC. For macrophage depletion, clodronate-filled
liposomes (200 l) (provided by Nico Van Rooijen) were injected into the tail
veins of 4- to 5-week-old C57BL/6 mice (42). PBS and empty liposomes (200
l) were injected as controls. The next day, mice were anesthetized with
isoflurane and inoculated i.h. with 500 PFU of A59 or ns2-H126R in 50 l of
PBS with 0.75% BSA.
Histology and immunohistochemistry. Brains and livers were removed and
fixed overnight in 4% paraformaldehyde. Tissues were embedded in paraffin and
sectioned, and sections were blocked with 10% normal donkey serum. The liver
sections were stained with hematoxylin and eosin, and immunostaining was
performed using a monoclonal antibody against MHV nucleocapsid (N) protein
(1:20 dilution; kindly provided by Julian Leibowitz) or using F4/80 (1:50 dilution;
Invitrogen). Staining was developed using an avidin-biotin-immunoperoxidase
technique according to the manufacturer’s directions (Vector Laboratories).
Astrocyte and microglia isolation. Primary mixed glial cultures were estab-
lished as described previously (32). The brains of 1- to 3-day-old neonatal
C57BL/6 mice were dissociated by repeated pipetting (approximately 20 times)
and were passed through 75-m nylon mesh. The cells were washed once in cold
PBS and cultured in DMEM (high glucose) supplemented with 10% FBS and 1%
penicillin-streptomycin. The medium was changed on days 3, 5, and 7 for astro-
cytes and on day 3 only for microglia. On day 10, flasks were shaken for 2 h at
260 rpm to remove nonadherent cells (microglia). The remaining adherent as-
trocytes were detached with trypsin-EDTA and replated. The microglia were
plated, and the medium was changed 30 min after plating to remove any non-
adherent cells. Astrocyte and microglial cultures were each 95% pure (1).
BMM isolation. Primary BMM were generated from the hind limbs of 6- to
8-week-old B6 or IFNAR/ mice as described previously (3). Macrophages
were cultured in DMEM supplemented with 10% FBS, 20% L929 cell condi-
tioned medium, 1 mM sodium pyruvate, 25 mM HEPES, and 1% penicillin-
streptomycin and were harvested on day 6 after plating.
qRT-PCR. RNA was isolated with an RNeasy minikit (Qiagen, Valencia, CA).
Real-time quantitative reverse transcriptase PCR (qRT-PCR) was performed as
described previously (29, 32). Briefly, 350 ng of total RNA (either from cells or
from tissue) was transcribed into cDNA by use of a Superscript III reverse
transcription kit (Invitrogen), using a total reaction mix volume of 20 l. Two
microliters of cDNA was combined with 12.5 l of iQ5 SYBR green mix (Bio-
Rad, Hercules, CA), 6.5 l diethyl pyrocarbonate (DEPC)-treated water, and 4
l primer mix (5 M concentration of each primer), DNA was amplified using
an iQ5 iCycler (Bio-Rad), and cycle threshold (CT) values were recorded. There
is an inverse relationship between the CT value and mRNA concentration, and
each CT unit represents a 2-fold difference in mRNA concentration. Basal ISG
mRNA levels were expressed as CT values relative to actin mRNA [CT 
CT(ISG)  CT(-actin)]. Induced ISG mRNA expression levels were expressed as
fold changes relative to mock infection levels, using the variable 2CT. All
primer sequences and thermocycle protocols for different primers are available
upon request.
Western immunoblots. Cells were lysed in RIPA buffer (50 mM Tris, pH 8.0,
150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
SDS) containing protease inhibitors (Roche). Protein concentrations were mea-
sured using a DC protein assay kit (Bio-Rad). Equal quantities of protein were
analyzed by 10% SDS-polyacrylamide gel electrophoresis. Following electropho-
retic transfer, polyvinylidene difluoride (PVDF) membranes were blocked with
5% nonfat milk and then probed with polyclonal antibodies directed against
MDA5 (Alexis), IFIT1, IFIT2 (Affinity Bioreagents), and tubulin (Abcam). The
blots were visualized using ECL reagent (GE) and detected under an Intelli-
gent dark box II (Fujifilm). ISG protein levels were normalized to tubulin levels
by use of ImageJ software (NIH).
IFN-/ ELISA. The amounts of IFN-/ protein in supernatants of MHV-
infected BMM or liver homogenates were quantified by use of a commercial
capture enzyme-linked immunosorbent assay (ELISA) kit (PBL Laboratories,
Piscataway, NJ) according to the manufacturer’s instructions.
Interferon sensitivity assay. L2 cells, astrocytes, and BMM were pretreated
with 0, 1, 10, 100, or 1,000 IU/ml universal human IFN- (PBL). After treatment
for 24 h for L2 cells and astrocytes and for 6 h for BMM, cells were washed once
with cold PBS and then infected with MHV at a multiplicity of infection (MOI)
of 1. At 18 h postinfection (p.i.) for L2 cells, 48 h for astrocytes, and 14 h p.i. for
BMM, cells and supernatants were combined and stored at 80°C. Cells were
lysed by two freeze-thaw cycles, and combined cellular and released virus titers
were determined by plaque assays on L2 cells.
Statistical analysis. An unpaired two-tailed t test was used to determine
statistical significance. All data were analyzed with GraphPad Prism software
(GraphPad Software, Inc., CA).
RESULTS
Disruption of the JHM.WU ns2 gene attenuates viral repli-
cation in the liver but not in the brain. We have previously
shown that amino acid substitutions of the predicted cata-
lytic residues (His46A and His126R mutations) of the A59
ns2 gene confer attenuation of viral replication in the liver
but not in the brain in C57BL/6 (B6) mice (33). We subse-
quently obtained similar results in a comparison of a natu-
rally occurring deletion mutant of ns2 (JHM.WU-ns2)
with its wt counterpart (JHM.WU) (obtained from Stuart
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Siddell; originally named MHV Wb1 and MHV Wb3, re-
spectively [36]). The ns2 mutant has a 318-base deletion of
the 5	 end of the ns2 open reading frame (ORF 2a), includ-
ing the transcription regulatory sequence (TRS) required
for transcription. The 50% lethal dose (LD50) of JHM.WU-
ns2 after intranasal inoculation is approximately 60 to 80
PFU, with no significant difference in lethality between wild-
type and ns2 JHM.WU strains (S. Perlman and J. Leibow-
itz, personal communication; L. Zhao, unpublished data).
As expected, the two isolates replicated similarly in the
brain following i.c. infection (Fig. 1A). We quantified virus
titer and antigen spread at day 5 postinfection, the peak of
virus replication in both organs (21, 22). While JHM iso-
lates, including the extremely neurovirulent JHM.SD strain
used most often in our lab (referred to as rJHM), generally
do not infect the liver even at very high doses (2, 7, 22), we
were surprised to find that JHM.WU replicated efficiently in
the liver following i.c. inoculation; as with the previously
published A59 ns2 mutants, the viral titers were lower in the
livers of mice infected with JHM.WU-ns2 (approximately
32-fold; P  0.005) than in those of mice infected with
wild-type JHM.WU (Fig. 1A). Consistent with these find-
ings, there was no obvious difference in the amount of viral
antigen staining, as assessed by staining with anti-MHV N
monoclonal antibody, in brain sections from JHM.WU-
and JHM.WU-ns2-infected mice; however, infection with
JHM.WU caused hepatocellular necrosis that colocalized
with MHV antigen staining, while infection of JHM.WU-
ns2 induced no necrosis and only small, scattered foci of
antigen staining (Fig. 1B).
We next compared the replication of each ns2 mutant with
that of its respective wt virus following infection by the i.h.
route, which typically produces very high levels of MHV A59
replication in the liver, peaking at day 5 postinfection (22). As
with i.c. infection, JHM.WU-ns2 titers in the liver were sig-
nificantly lower (55-fold lower; P  0.001) than those of wt
JHM.WU, and ns2-H126R titers were much lower (1,520-fold
lower; P 
 0.001) than those of wt A59 (Fig. 1C). The viral
load of JHM.WU was actually higher (about 14-fold; P 
0.0038) than that of MHV A59, demonstrating that in contrast
to all other known JHM isolates, JHM.WU is highly hepato-
tropic as well as highly neurovirulent.
FIG. 1. Replication of JHM.WU and JHM.WU-ns2 in the brain and liver after i.c. inoculation. (A) Four- to 5-week-old B6 mice were infected
i.c. with 10 PFU of JHM.WU or JHM.WU-ns2 (n  5). At day 5 postinfection, mice were sacrificed and the viral loads in the brain and liver
were determined by plaque assay on L2 cells. The error bars represent the standard errors of the means (SEM). (B) MHV antigen was detected
by staining with anti-MHV N monoclonal antibody (n  3). (C) B6 mice were infected i.h. with 500 PFU of JHM.WU, JHM.WU-ns2, A59, or
ns2-H126R (n  5). At day 5 postinfection, mice were sacrificed and viral loads in the liver were determined by plaque assay on L2 cells. The
dashed line represents the limit of detection, and the error bars represent the SEM. (D) Livers and brains were harvested from uninfected B6 mice
(n  8), and total RNA was isolated. Basal mRNA levels of ISGs were quantified by qRT-PCR and normalized to the actin mRNA level [CT 
CT(ISG)  CT(-actin)]. The CT values for -actin were approximately the same in the brain and the liver. The line represents the limit of detection,
and the error bars represent the SEM. Asterisks indicate that differences are statistically significant (*, P 
 0.05; **, P 
 0.01; ***, P 
 0.001).
Data shown were derived from one representative experiment of two.
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Based on previous reports that basal expression levels of
ISGs play an important role in host defense against viral inva-
sion and may thus be partially responsible for determining
susceptibility to viral infection (14, 48), we compared the basal
mRNA expression levels in the brain and liver of a group of
ISGs encoding both IFN signaling and antiviral molecules.
Using qRT-PCR, we found that the basal mRNA expression
levels of this group of ISGs were significantly higher (4- to
16-fold) in the liver than in the brain (P 
 0.05), suggesting
that the liver may be better prepared than the brain to mount
an early innate antiviral response (Fig. 1D). This difference
may contribute to the liver-specific attenuation of ns2 mutants.
ns2 mutations attenuate replication in wt but not IFNAR/
macrophages or microglia. The in vitro replication kinetics of
each ns2 mutant (ns2-H126R and JHM.WU-ns2) were sim-
ilar to those of the respective wt viruses in murine 17Cl-1 and
DBT fibroblast cell lines (33, 36). However, these cell types
neither produce any detectable type I IFN in response to MHV
infection nor restrict MHV infection when treated with exog-
enous IFN- (32, 43, 47). In order to compare the abilities of
ns2 mutants and wt viruses to replicate in cell types in which
MHV does induce a type I IFN response, we assessed the
replication kinetics of both sets of wt and ns2 mutant viruses in
BMM and microglia and compared them to the respective
replication patterns in a mouse fibroblast cell line (L2) and in
primary mouse astrocytes, a cell type that produces minimal
levels of IFN- mRNA only late during MHV infection. In L2
fibroblasts and astrocytes, the replication kinetics of the ns2
mutant viruses were comparable to those of their respective wt
counterparts. However, in BMM, the peak titers (at 12 h p.i.)
of the ns2-H126R and JHM.WU-ns2 viruses were approxi-
mately 115-fold and 20-fold lower, respectively, than those
of the wt viruses (Fig. 2). Strikingly, the replication kinetics
of both ns2 mutant viruses were restored to wt levels in
IFNAR/ BMM and microglia (Fig. 3) after infection at an
MOI of either 1 PFU/cell (Fig. 3A, B, E, and F) or 0.01
PFU/cell (Fig. 3C and D); the latter condition would be
expected to emphasize any replication defect in the mutants.
In microglia, the resident macrophages of the CNS, ns2-
H126R and JHM.WU-ns2 had similar phenotypes to those
observed in BMM, although the attenuation of replication
in wt cells was not as severe (Fig. 2). In addition, replication
of the ns2 mutants relative to their wt counterparts was
decreased only slightly in BMM isolated from mice in which
expression of MDA5, the major sensor for detection of
MHV RNA in this cell type (31), had been ablated
(MDA5/ mice) (data not shown). Taken together, these
results suggest that the attenuation of ns2 mutants is specific
to macrophages/microglia and is related to an increased
sensitivity to IFN induction or signaling.
ns2 mutants induce type I IFN production to the same
extent as wt virus. To investigate the effect of ns2 on IFN
production, the levels of IFN- mRNA and protein induced by
MHV infection of several cell types were analyzed by qRT-
PCR and ELISA, respectively. In L2 cells (Fig. 4A) and pri-
mary astrocytes (Fig. 4B), IFN- mRNA was detected only at
very low levels and late in infection, and IFN- protein could
not be detected after MHV infection (data not shown), con-
sistent with previous studies with cell lines. In contrast, Sendai
virus (SeV) induced much higher levels of IFN- mRNA than
those induced by MHV, demonstrating that this cell type is
capable of expressing type I IFN (32, 47). Importantly, there
was no significant difference (P 0.05) between IFN- mRNA
levels induced by ns2 mutant viruses and their corresponding
wt viruses. There were also no significant differences in induc-
tion of IFN- or IFN-4 mRNA between BMM infected with
FIG. 2. Mutation of the ns2 gene in the A59 and JHM.WU backgrounds attenuates viral replication in BMM and microglia. L2 cells, primary
astrocytes, microglia, or BMM (as indicated) were infected with A59, ns2-H126R, JHM.WU, or JHM.WU-ns2 at an MOI of 1 PFU/cell. At the
indicated time points postinfection, cells were lysed in their medium by freeze-thawing, and titers were determined by plaque assay on L2 cells.
The data are from one representative experiment of at least two, each performed in triplicate.
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ns2 mutant viruses and those infected with their wt counter-
parts at 6 h p.i. (A59) (Fig. 4C) or 9 h p.i. (JHM.WU) (Fig.
4D), the time points after which wt and mutant growth curves
diverged (Fig. 2). To compare type I IFN induction at later
time points under conditions in which IFN expression was
due only to the initial induction by virus infection rather
than to type I interferon receptor (IFNAR)-dependent am-
plification of IFN- expression, we repeated the experiment
with IFNAR/ BMM. Again, there were no significant
differences (P  0.05) in IFN- mRNA or protein induction
between BMM infected with ns2 mutant and wt viruses at
time points up to 12 h p.i. (Fig. 4F). Unexpectedly, both
JHM.WU-ns2 and JHM.WU induced much lower levels of
IFN- mRNA, with no detectable IFN- protein, than those
induced by wt or ns2 mutant A59 (Fig. 4E). These data show
that ns2 does not compromise the IFNAR-independent in-
duction of IFN- and, in addition, that the highly virulent
JHM.WU isolate is a very weak inducer of type I IFN.
ns2 mutants exhibit increased sensitivity to IFN signaling in
microphages/microglia but not in L2 cells or astrocytes. To
investigate whether ns2 is able to antagonize the antiviral ef-
fects of IFN signaling, L2 cells, primary astrocytes, and BMM
were treated with increasing concentrations of IFN- to induce
ISGs and an antiviral state and were then infected with wt or
ns2 mutant MHV. As shown in Fig. 5A and B, ns2 mutants (on
both A59 and JHM.WU backgrounds) displayed similar sen-
sitivities to IFN- to those of their wt counterparts in both L2
cells and primary astrocytes. However, ns2-H126R showed en-
FIG. 3. ns2 mutants replicate to the same extent as wt viruses in
BMM and microglia from IFNAR/ mice. IFNAR/ BMM were
infected with the indicated viruses at an MOI of 1 PFU/cell (A and B)
or 0.01 PFU/cell (C and D), and IFNAR/ microglia were infected at
an MOI of 1 PFU/cell (E and F). At the indicated times postinfection,
titers of viruses in the cell lysates and supernatants were determined by
plaque assay on L2 cells. The data are from one representative exper-
iment of two, each performed in triplicate.
FIG. 4. ns2 does not antagonize IFN production. (A and B) L2 cells
and primary astrocytes were infected with A59, ns2-H126R, JHM.WU,
or JHM.WU-ns2 at an MOI of 1 PFU/cell. At 24 h p.i., IFN-mRNA
was quantified by qRT-PCR. (C and D) BMM were infected with A59,
ns2-H126R, JHM.WU, or JHM.WU-ns2 at an MOI of 1. At 6 h p.i.
for A59 and ns2-H126R and 9 h p.i. for JHM.WU and JHM.WU-ns2,
IFN- and IFN-4 mRNAs were quantified by qRT-PCR. (E) At 12 h
p.i., IFN- protein in the medium above infected BMM was quantified
by ELISA. (F) IFNAR/ BMM were infected with A59, ns2-H126R,
JHM.WU, or JHM.WU-ns2 at an MOI of 1 PFU/cell. The kinetics of
IFN-mRNA expression were quantified by qRT-PCR. The error bars
represent the SEM (n  4). ND, not detectable.
10062 ZHAO ET AL. J. VIROL.
hanced sensitivity to IFN in BMM, especially after low-dose
IFN- pretreatment (Fig. 5C and D). Pretreatment of BMM
with 1 IU/ml and 10 IU/ml IFN- produced 20- and 120-fold
inhibition, respectively, of ns2-H126R, compared with 2-fold
and 4-fold inhibition of wt virus. Similarly, pretreatment of
microglia with 10 IU/ml IFN- produced a 3,980-fold inhi-
bition of ns2-H126R, compared with a 161-fold inhibition of
wt virus at 24 h p.i. (Fig. 5E). These differences suggest that
A59 ns2 confers the ability to antagonize IFN-induced an-
tiviral responses in macrophages and microglia. In contrast,
JHM.WU-ns2 displayed similar or only slightly decreased
sensitivity to IFN pretreatment in BMM compared with wt
JHM.WU (Fig. 5C and D).
Interestingly, JHM.WU was less sensitive than A59 to the
effects of IFN- pretreatment of both BMM and primary as-
trocytes (Fig. 5B and C). In primary astrocytes, pretreatment
with 1,000 IU/ml IFN- produced a 1,210-fold inhibition for
A59, compared with a 70-fold inhibition for JHM.WU. In
BMM, the same treatment produced an 80-fold inhibition for
A59, compared with a 20-fold inhibition for JHM.WU. The
relative resistance of the JHM.WU isolate to IFN signaling in
primary cells (astrocytes and BMM) may contribute to its very
high virulence. The only minor sensitivity of JHM.WU to IFN
pretreatment of BMM suggests that genes other than the
ns2 gene confer type I IFN resistance to both JHM.WU and
JHM.WU-ns2, which could also explain the relatively small
difference in resistance to IFN signaling between wt and ns2
mutant JHM.WU-ns2 in BMM, as well as the relatively
efficient replication of JHM.WU and JHM.WU-ns2 in the
liver compared to that of A59 and A59-ns2H126R (Fig. 1).
Macrophages and microglia express high basal levels of
ISGs relative to L2 fibroblasts and astrocytes. To further elu-
cidate the mechanisms responsible for differential restriction
of MHV replication by IFN- treatment in different cell types
(Fig. 5), we compared the basal mRNA expression levels of a
group of ISGs in macrophages and microglia with those in L2
fibroblasts and primary astrocytes. Not unexpectedly, the basal
mRNA expression levels for several ISG proteins involved in
viral detection and IFN signaling (MDA5, STAT1, IRF7, and
IFNAR1), as well as those for several genes encoding antiviral
activities (IFIT1, IFIT2, and ISG15), were higher in macro-
phages and microglia than in L2 cells and astrocytes, explain-
ing at least in part the differences in response to IFN pretreat-
ment (Fig. 6A to G). The expression level of the mRNA
encoding suppressor of cytokine signaling protein 3 (SOCS3)
showed the opposite pattern, with lower expression in BMM
than in other cell types (Fig. 6H). The low-level expression of
the SOCS3 mRNA may also contribute to enhancing the re-
sponse of BMM to IFN treatment (34). Consistent with the
mRNA levels, the protein levels of MDA5, IFIT1, and IFIT2
were highest in macrophages and lowest, even undetectable, in
L2 cells (Fig. 6I). The basal level of MDA5 expression is
probably an important determinant of restriction of MHV
infection, as it is the only known pattern recognition receptor
identified in the cell types being considered here.
ns2 suppresses expression of multiple mRNAs encoding ISG
proteins with antiviral activities in BMM. To investigate
whether ns2 expression inhibits ISG mRNA induction by IFN,
BMM were infected with wt A59 or ns2-H126R and treated
with IFN- to enhance the induction of ISGs at 6 h p.i. (at
FIG. 5. Mutation of ns2 confers increased sensitivity to IFN in BMM.
Murine L2 fibroblasts (A), astrocytes (B), or BMM (C) were pretreated
with increasing doses of IFN-. Twenty-four hours after IFN- treatment
for L2 and astrocytes or 6 h after treatment for BMM, cells were infected
with the indicated viruses at an MOI of 1 PFU/cell. At 18 h p.i. for L2, 48 h
for astrocytes, and 14 h p.i. for BMM, virus titers (cell-associated and
released titers combined) were determined by plaque assay on L2 cells.
(D) Relative changes in virus titers in BMM. (E) Microglia were pre-
treated with 10 IU/ml of IFN- or mock treated for 6 h and then infected
with A59 or ns2-H126R at an MOI of 1 PFU/cell. At the indicated time
points postinfection, virus titers (cell-associated and released titers com-
bined) were determined by plaque assay on L2 cells. The data are from
one representative experiment of two, performed in triplicate.
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which time the titers of both viruses were approximately the
same) (18, 27). At several times post-IFN treatment, expres-
sion of mRNAs for a group of ISGs was quantified. As shown
in Fig. 7, mRNAs encoding antiviral activities, i.e., IFIT1,
IFIT2, and ISG15, were slightly enhanced at 0.5 h (Fig. 7A)
and induced at significantly higher (P
 0.05) levels at 1 h (Fig.
7B) post-IFN treatment by ns2-H126R than by wt A59, while
there were no significant differences in induction of mRNAs
encoding MDA5, STAT1, or IRF7 between cells infected by
these two viruses. By 1.5 h posttreatment, the replication of ns2
was significantly inhibited compared to that for wt rA59 (Fig.
2), and there were no differences observed in ISG expression
(data not shown). This indicates that ns2 inhibits neither in-
duction of the canonical JAK-STAT pathway nor expression of
the several signaling ISGs assessed but rather suppresses or
delays the expression of specific antiviral ISGs, consistent with
the finding that even wt A59 replication is restricted to a
significant extent in BMM (Fig. 6C).
Replication of the ns2-H126R mutant virus in the liver is
enhanced in macrophage-depleted mice. Based on the pheno-
type of ns2 mutant viruses relative to wt viruses in BMM in
vitro and the greatly reduced ability of these mutants to repli-
cate in the liver in vivo, we hypothesized that IFN signaling in
macrophages presents a barrier to replication in the liver and
therefore predicted that the ns2 mutants would regain the
ability to replicate in the liver after in vivo depletion of mac-
FIG. 6. Basal ISG mRNA and protein expression in different cell types. RNAs were purified from uninfected BMM, microglia, and astrocytes
derived from B6 mice. The basal levels of ISG mRNA expression, normalized to -actin mRNA levels, were quantified by qRT-PCR. (A) MDA5;
(B) IRF-7; (C) STAT1; (D) IRNAR1; (E) IFIT1; (F) IFIT2; (G) ISG15; (H) SOCS3. Data were derived from one representative experiment of
two; the error bars represent the SEM (n  4). (I) Basal protein expression levels of MDA5, IFIT1, IFIT2, and tubulin were assessed by Western
immunoblotting. ISG protein levels were normalized to the tubulin level in each cell type; the ratio of ISG to tubulin is indicated below each band.
FIG. 7. ns2 suppresses specific ISG mRNA expression in BMM. BMM were infected with A59 or ns2-H126R at an MOI of 1. At 6 h p.i., cells
were treated with 1,000 IU/ml IFN-. The cells were harvested at 0.5 (A) and 1 (B) h post-IFN- treatment, and RNA was extracted. ISG mRNA
expression was quantified by qRT-PCR (n  4) and expressed as the fold change compared to untreated cells. The data were derived from one
representative experiment of two. The error bars represent the SEM.
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rophages. To test this hypothesis, we used the A59 background
pair of viruses because the difference in wt A59 and ns2-
H126R replication was quite dramatic and the ns2 mutant
caused only minimal hepatitis, while JHM.WU-ns2, although
attenuated compared to JHM.WU, still replicated to signifi-
cant titers in the liver. Thus, clodronate-filled liposomes were
injected intravenously into mice to deplete all macrophages
(37, 42), including the Kupffer cells, resident macrophages
found in the liver sinusoids that comprise 8% of liver cells
(28, 38). PBS and liposomes lacking clodronate were injected
as negative controls. Twenty-four hours after liposome trans-
fer, mice were infected i.h. with 500 PFU of A59 or ns2-H126R
and were sacrificed at 5 days postinfection (dpi), at which time
the livers were harvested. Efficient depletion of macrophages
in mice receiving clodronate-filled liposomes was demon-
strated by staining liver sections from uninfected mice with a
monoclonal antibody against F4/80, a mouse macrophage-spe-
cific marker (Fig. 8A). Hepatitis was evaluated by staining with
hematoxylin and eosin. Following ns2-H126R infection, there
were necrotic foci and parenchymal inflammation in liver sec-
tions from clodronate-liposome-treated mice; this was in con-
trast to the sections from PBS-treated mice, which exhibited no
obvious pathological changes. Staining of sections from infected
mice with anti-MHV N monoclonal antibody demonstrated a
dramatic increase in the amount of ns2-H126R antigen localized
to necrotic foci in liver sections from clodronate-liposome-treated
mice compared with sections from PBS-treated mice (Fig. 8B),
while more modest increases in antigen were observed in sections
from A59-infected mice. These observations were confirmed by
quantifying viral titers in the liver. The viral titers of A59 and
ns2-H126R in livers from mice treated with control liposomes
were comparable with those from mice treated with PBS, indi-
cating that the liposomes had no effect on viral replication. After
clodronate-liposome treatment, the viral loads in the liver were
increased 553-fold (P 
 0.0001) for the ns2-H126R mutant-in-
fected mice compared with those from ns2-H126R-infected mice
treated with control liposomes. In contrast, there was only a
10-fold change (P  0.0012) for clodronate-liposome-treated
A59-infected mice compared with control liposome-treated A59-
infected mice (Fig. 8C and D).
FIG. 8. Macrophage depletion restores the virulence of ns2-H126R. Four-week-old B6 mice were injected intravenously in the tail vein with
clodronate-liposomes. Control mice were similarly treated with PBS or empty liposomes. The next day, mice were injected intrahepatically with
500 PFU A59 or ns2-H126R or with PBS. (A) At 5 days postinfection, livers from mock-infected mice were harvested and stained for F4/80 (n 
3). (B) Liver sections were stained with hematoxylin and eosin to detect pathological changes and with anti-MHV N monoclonal antibody to detect
viral antigen expression (n 3). (C) Virus titers in A59- or ns2-H126R-infected livers were determined by plaque assay. The dashed line represents
the limit of detection, and the error bars represent SEM (n  5). (D) Fold change of virus titer of A59 or ns2-H126R in livers from mice treated
with clodronate-liposomes versus livers from those treated with empty liposomes or PBS. IFN- (E) and IFN- (F) protein levels in A59- or
ns2-H126R-infected livers were quantified by ELISA. The error bars represent SEM (n  5).
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The IFN-/ protein levels induced in mouse livers by the
ns2-H126A mutant and wt A59 were quantified by ELISA.
After clodronate-liposome treatment, the levels of IFN- in wt
and ns2 mutant virus-infected mouse livers were significantly
lower than those in control liposome-treated infected mice
(P 0.0158 for A59 and P 0.0032 for ns2-H126R) (Fig. 8E).
This indicated that macrophages were the main source of
IFN- in the mouse liver after MHV infection. Interestingly,
after clodronate-liposome treatment, the levels of IFN- in
A59- and ns2-H126R-infected mouse livers were higher than
those in infected mice treated with control liposomes (P 
0.0049 for A59 and P  0.005 for ns2-H126R) (Fig. 8F). This
was most likely due to increased viral replication in plasmacy-
toid dendritic cells (pDCs), reported to be the main source of
IFN- expression after MHV infection (5). Nevertheless, the
increased levels of IFN- and the residual IFN- in the liver
were not sufficient to prevent efficient replication in the mac-
rophage-depleted livers.
DISCUSSION
We show here, by comparison of wt and ns2 mutant MHV,
that the abilities of MHV to replicate efficiently in BMM and
to resist IFN treatment of BMM in vitro correlate with the
ability to replicate efficiently in the liver and induce hepatitis.
The observation that ns2 mutant viruses were able to replicate
to the same extent as wt viruses in IFNAR/ BMM indicates
that ns2 confers the ability to resist type I IFN signaling. These
results, together with the finding that depletion of macro-
phages in vivo allows ns2-H126R to replicate in the liver and to
induce hepatitis, led us to speculate that MHV must replicate
successfully in Kupffer cells (liver macrophages) within the
sinusoids of the liver in order to enter the liver parenchyma,
infect hepatocytes, and induce hepatitis. Indeed, both hepato-
tropic and nonhepatotropic MHV strains can replicate in pri-
mary hepatocytes in vitro (31), supporting the notion that it is
replication in a nonhepatocyte cell type that determines the
ability to infect the liver and induce hepatitis (31). However, it
is not possible to distinguish the effects of the loss of Kupffer
cells from those of the loss of other macrophages, and it is
possible that replication in macrophages other than Kupffer
cells may also contribute to host defense from hepatitis. These
data are consistent with a previous study utilizing mice with a
cell-type-specific IFNAR ablation that concluded that macro-
phages and, to a lesser extent, DCs were the most important
cell type for IFN signaling-mediated restriction of MHV-in-
duced hepatitis (4). In addition, a study utilizing a lymphocytic
choriomeningitis virus (LCMV) mouse model of hepatitis con-
cluded that IFN signaling in tissue-resident macrophages pro-
vides a barrier to infection of the liver parenchyma (19).
Interestingly, in mice depleted of macrophages, the level of
IFN- in the liver was significantly lower than that in control
mice, despite the fact that the viral loads in the livers of de-
pleted mice were higher; this suggests that macrophages are a
major source of IFN- in the mouse liver during MHV infec-
tion. In contrast, the level of IFN- was significantly increased
in the livers of macrophage-depleted mice, most likely due to
an increased viral load in the liver; this is consistent with a
previous report that pDCs are a major source of IFN- in
MHV-infected mice (5). The residual level of IFN- and in-
creased amount of IFN- were unable to protect the host in
the absence of macrophages, again supporting the hypothesis
that IFN signaling in macrophages is an important component
of host protection from MHV.
While wild-type MHV is susceptible to the antiviral effects of
IFN-/, we have shown that MHV is able to partially resist
IFN--induced signaling in 293T cells (29) and now in several
other cell types, including BMM (Fig. 8). This suggests that
MHV may be able to reduce the expression and/or resist the
antiviral effects of one or more of the many ISG proteins that
have direct antiviral activity (9). In BMM, MHV did partially
inhibit the induction by IFN of the mRNAs encoding ISG15,
IFIT2, and IFIT1, three ISG proteins with antiviral activity, but
not the induction of the mRNAs encoding MDA5, STAT1,
and IRF7, three molecules involved in the detection of viral
RNA or in the canonical type I IFN signaling pathway. This
indicates that ns2 is not able to inhibit the STAT-dependent
pathway of ISG induction and suggests that there are differ-
ences in the pathways leading to induction of subgroups of
ISGs (Fig. 7). In our earlier studies, we also observed that
MHV infection differentially regulated the induction of differ-
ent ISGs in 293T cells (29). There are several reports that type
I IFN signaling may be activated by noncanonical signaling
pathways in a cell-type-dependent manner (6, 35, 41). For
example, comparison of ISG expression in wt and IKKε-defi-
cient cells demonstrated that transcription of some but not all
ISGs required IKKε expression; these IKKε-dependent genes
included the IRF-7 and STAT1 genes but not several other
ISGs encoding proteins with direct antiviral activities (40).
These groupings are consistent with our observation that MHV
expressing wt ns2 inhibited the transcription of antiviral ISGs
but not that of STAT1 and IRF7. Together, these results sup-
port the hypothesis that different activation pathways result in
expression of different subgroups of ISGs.
Little is known about which type I IFN-induced antiviral
effectors are most important for host restriction of MHV. We
previously found that MHV is relatively resistant to IFN treat-
ment of fibroblast cell lines (as in Fig. 5A), while similar IFN
treatment completely restricts Newcastle disease virus (NDV)
replication (32). Furthermore, during coinfections with MHV
and either SeV or NDV, pretreatment of mouse fibroblasts
with IFN- is still unable to restrict MHV infection, while both
of the other viruses fail to replicate even in the presence of
MHV (29, 32). This suggests that either different antiviral
activities are responsible for restricting each virus or MHV has
a mechanism for avoiding antiviral activity that does not pro-
tect the coinfecting virus. Comparison of the data presented
for ns2 mutant and wt viruses suggests that the expression or
antiviral activities of ISGs may be cell type specific, as ns2
confers increased IFN resistance in BMM and microglia but
not in astrocytes, in which wt and ns2 mutant viruses are
equally resistant to IFN signaling (Fig. 5B). Recently, a meth-
yltransferase mutant of MHV (nsp16-D130A) was shown to
replicate less well than wt A59 in BMM from B6 mice but
equally well in BMM derived from IFIT1/ mice (49), sug-
gesting that RNA methylation may allow MHV to avoid the
antiviral effect of IFIT1 in macrophages. However, IFIT1 did
not preferentially inhibit nsp16-D130A replication when it was
overexpressed in murine fibroblasts. This underscores the cell-
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type-specific differences in virus interaction with the host type
I IFN response.
Since most JHM isolates, including the JHM.SD strain used
most often by our lab, are highly neurotropic but replicate
minimally, if at all, in the liver (2), we were surprised to find
that the JHM.WU strain used in these studies (originally called
MHV Wb3 [36]), which was isolated after multiple passages in
tissue culture, replicated to high titers in the liver, and induced
severe hepatitis. Interestingly, JHM.WU exhibited less induc-
tion of IFN- in BMM (Fig. 4) and much higher resistance to
IFN pretreatment of primary cells (Fig. 5) than did A59. In
contrast to the ns2 mutant and wt A59 viruses, JHM.WU-ns2
and JHM.WU displayed similar resistances to IFN- in BMM.
Compared with wt JHM.WU, JHM.WU-ns2 did exhibit de-
creased replication in the mouse liver, although this attenua-
tion was also much less than that displayed by ns2-H126R
compared with the wild-type parent A59. The data suggest that
the ability of JHM.WU to inhibit IFN production and its high
resistance to IFN treatment together contribute to its high
hepatovirulence and that this evasion of the type I IFN re-
sponse is much less dependent on ns2. We infer that one or
more additional proteins encoded by the JHM.WU genome
may strongly suppress type I IFN production and/or signaling.
Several MHV-encoded proteins have been reported to an-
tagonize type I IFN signaling in various cell types. The nucleo-
capsid (N) protein of A59 expressed by a recombinant vaccinia
virus was reported to inhibit RNase L activity in 17CI-1 and
HeLa cells, likely due to its RNA-binding properties (45). The
papain-like protease (PLP), encoded within the coronavirus
replicase locus and expressed as part of nonstructural protein
3 (nsp3), has deubiquitinating as well as protease activity.
While SARS PLP interferes with the IRF3 and NF-B path-
ways (46), it not clear if the corresponding MHV protein has
these two activities (11). Coronavirus nsp1 was reported to
antagonize the effects of IFN- in macrophages (50), and mu-
tation of nsp1 conferred attenuation of replication in the liver
and spleen; however, it is difficult to determine whether the
effect on type I IFN signaling is a direct or indirect effect of the
ability of nsp1 to degrade host cell mRNA (11, 15). The ns5a
protein of A59 was recently reported to have type I IFN an-
tagonist activity (17), but ns5a mutants, in contrast to ns2
mutants, were sensitive to IFN in astrocytes and murine fibro-
blasts as well as in BMM, and their replication was attenuated
in the CNS as well as in the liver (data not shown). It is still not
clear which of these proteins play major roles in MHV patho-
genesis in vivo. Studies are under way to use reverse genetics to
map the gene(s) of JHM.WU responsible for its ability to
antagonize type I IFN and for its unusually strong virulence in
the liver.
Our results suggest that the interaction of MHV with the
early type I IFN response is an important determinant of
cellular and organ tropism. More specifically, the basal level of
ISG expression is an important factor in permissiveness to viral
infection. Here we found that BMM have high basal expression
levels of mRNAs encoding ISG proteins, including MDA5,
STAT1, and other molecules crucial for recognizing viral in-
vasion and producing an antiviral environment, and a lower
basal expression level of SOCS3 mRNA. Indeed, while BMM
expressed high basal levels of MDA5, IFIT1, and IFIT2 pro-
teins, these ISG proteins were undetectable in uninfected L2
cells. BMM from IFNAR/ mice have lower basal and in-
duced levels of ISGs (our unpublished data), consistent with
the robust replication of ns2 mutants in such BMM. In addi-
tion, liver tissue has higher basal levels of these ISGs than
brain tissue, consistent with the organ specificity of ns2 mutant-
associated attenuation. Interestingly, CEACAM1a, the only
known receptor for MHV, is expressed at a significantly higher
level in the liver than in the brain, where it is barely detectable
(1), while MHV A59 replicates robustly in both organs. There-
fore, we suggest that the difference in ISG levels may compen-
sate for the very different levels of receptor. We believe that
this relationship between receptor level and the preparedness
of a cell type for defense against viral invasion will be impor-
tant in determining viral tropism and should be investigated
further.
The mechanism by which ns2 antagonizes the type I IFN
response is not known. As a member of the LigT-like family II
of the superfamily of 2H-phosphoesterases, ns2 is predicted to
have 2	,3	- and/or 1,2-cyclophosphodiesterase or ligase activ-
ities and may be involved in modification of viral or host RNA
(20). While no enzymatic activity has yet been reported for ns2,
the abilities to act as a virulence factor in the liver and to
antagonize IFN signaling both map to the predicted catalytic
His residues (33). Among the members of the 2H-phospho-
esterase superfamily, ns2 is most closely related to the human
CGI18 and rat AKAP18 proteins, which, like ns2, have not yet
been shown to have enzymatic activities but have important
nonenzymatic activities as anchoring proteins that may poten-
tially regulate multiple signaling pathways (10, 16, 20). Efforts
are under way in our lab to determine if ns2 does indeed have
a phosphodiesterase activity. Once this is determined, we can
design experiments to begin to uncover the mechanisms un-
derlying its ability to antagonize the IFN response as well as its
role in pathogenesis in the liver.
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